{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:00:33Z","timestamp":1761490833449,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T00:00:00Z","timestamp":1604707200000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rbmojournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive BioMedicine Online"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.rbmo.2019.07.028","type":"journal-article","created":{"date-parts":[[2019,7,17]],"date-time":"2019-07-17T12:02:46Z","timestamp":1563364966000},"page":"795-801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study"],"prefix":"10.1016","volume":"39","author":[{"given":"Antoine","family":"Netter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Siles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Audrey","family":"Pivano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aubert","family":"Agostini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"journal-title":"Allergan,","article-title":"Allergan and Gedeon Richter announce positive phase III results for ulipristal acetate 5 and 10 mg in the treatment of uterine fibroids","year":"2017","key":"10.1016\/j.rbmo.2019.07.028_bib0001"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0002","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1093\/humrep\/det467","article-title":"Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo","volume":"29","author":"Barlow","year":"2014","journal-title":"Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0003","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1056\/NEJMra1209993","article-title":"Uterine Fibroids","volume":"369","author":"Bulun","year":"2013","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0004","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.rbmo.2018.04.050","article-title":"Gene expression changes in uterine myomas in response to ulipristal acetate treatment","volume":"37","author":"Courtoy","year":"2018","journal-title":"Reprod. Biomed. Online"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0005","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0006","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/GCO.0000000000000229","article-title":"Current management of myomas: the place of medical therapy with the advent of selective progesterone receptor modulators","volume":"27","author":"Donnez","year":"2015","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0007","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.fertnstert.2014.06.041","article-title":"With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice?","volume":"102","author":"Donnez","year":"2014","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0008","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.fertnstert.2014.10.038","article-title":"Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids","volume":"103","author":"Donnez","year":"2015","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0009","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1056\/NEJMoa1103182","article-title":"Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJMoa1103180","article-title":"Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids","volume":"366","author":"Donnez","year":"2012","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0011","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.fertnstert.2014.02.008","article-title":"Long-term treatment of uterine fibroids with ulipristal acetate*","volume":"101","author":"Donnez","year":"2014","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0012","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejogrb.2016.08.021","article-title":"Three-month treatment with ulipristal acetate prior to laparoscopic myomectomy of large uterine myomas: a retrospective study","volume":"205","author":"Ferrero","year":"2016","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0013","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1289\/ehp.5787","article-title":"Etiology and pathogenesis of uterine leiomyomas: a review","volume":"111","author":"Flake","year":"2003","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0014","unstructured":"Gedeon Richter PLC, 2016. Esmya (ulipristal acetate) (product information). Budapest, Hungary."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0015","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/humu.22612","article-title":"Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas","volume":"35","author":"K\u00e4mpj\u00e4rvi","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0002-9378(89)80046-8","article-title":"Mitotic activity in uterine leiomyomas during the menstrual cycle","volume":"160","author":"Kawaguchi","year":"1989","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0017","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/j.fertnstert.2017.07.097","article-title":"Quality of life with ulipristal acetate (UPA) treatment of symptomatic uterine fibroids (UF): VENUS II study","volume":"108","author":"Kroll","year":"2017","journal-title":"Fertility and Sterility"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5468\/ogs.2017.60.1.69","article-title":"Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist","volume":"60","author":"Lee","year":"2017","journal-title":"Obstet. Gynecol. Sci"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0019","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1097\/AOG.0b013e3181705d0e","article-title":"CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial","volume":"111","author":"Levens","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0020","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/j.jmig.2015.08.196","article-title":"The Selective Progesterone Receptor Modulator, Ulipristal Acetate, in the Management of Symptomatic Uterine Fibroids","volume":"22","author":"Leyland","year":"2015","journal-title":"J. Minim. Invasive Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0021","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1073\/pnas.1518752113","article-title":"Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers","volume":"113","author":"Mehine","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0022","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1302736","article-title":"Characterization of uterine leiomyomas by whole-genome sequencing","volume":"369","author":"Mehine","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0023","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.fertnstert.2011.03.079","article-title":"The FIGO classification of causes of abnormal uterine bleeding in the reproductive years","volume":"95","author":"Munro","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2010.09.059","article-title":"Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study","volume":"95","author":"Nieman","year":"2011","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0025","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bpobgyn.2008.04.002","article-title":"Incidence, aetiology and epidemiology of uterine fibroids","volume":"22","author":"Okolo","year":"2008","journal-title":"Best Practice & Research Clinical Obstetrics & Gynaecology, Uterine Fibroids"},{"key":"10.1016\/j.rbmo.2019.07.028_bib0026","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.fertnstert.2007.01.093","article-title":"Etiology, symptomatology, and diagnosis of uterine myomas","volume":"87","author":"Parker","year":"2007","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0027","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0002-9378(95)90077-2","article-title":"Progesterone: a critical role in the pathogenesis of uterine myomas","volume":"172","author":"Rein","year":"1995","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0028","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/AOG.0000000000002462","article-title":"Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas: A Randomized Controlled Trial","volume":"131","author":"Simon","year":"2018","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0029","article-title":"The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids","author":"Singh","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0030","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1933719114553451","article-title":"Unbiased and Efficient Estimation of the Volume of the Fibroid Uterus Using the Cavalieri Method and Magnetic Resonance Imaging","volume":"22","author":"Thrippleton","year":"2015","journal-title":"Reprod. Sci."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0031","unstructured":"Vifor Pharma Pty Ltd, 2017. Esmya (ulipristal acetate) (product information). Melbourne, Australia."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0032","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00270-007-9209-0","article-title":"MR reproducibility in the assessment of uterine fibroids for patients scheduled for uterine artery embolization","volume":"31","author":"Volkers","year":"2008","journal-title":"Cardiovasc. Intervent. Radiol."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0033","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/molehr\/gan004","article-title":"Progesterone receptor modulator CDB-2914 induces extracellular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells","volume":"14","author":"Xu","year":"2008","journal-title":"Mol. Hum. Reprod."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0034","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1210\/jc.2004-1569","article-title":"Progesterone receptor modulator CDB-2914 down-regulates proliferative cell nuclear antigen and Bcl-2 protein expression and up-regulates caspase-3 and poly(adenosine 5\u2019-diphosphate-ribose) polymerase expression in cultured human uterine leiomyoma cells","volume":"90","author":"Xu","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0035","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.fertnstert.2016.10.035","article-title":"Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays","volume":"107","author":"Yatsenko","year":"2017","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.rbmo.2019.07.028_bib0036","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejogrb.2018.03.026","article-title":"Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate","volume":"224","author":"Yun","year":"2018","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."}],"container-title":["Reproductive BioMedicine Online"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648319306613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472648319306613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:17:08Z","timestamp":1761466628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472648319306613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S1472648319306613"],"URL":"https:\/\/doi.org\/10.1016\/j.rbmo.2019.07.028","relation":{},"ISSN":["1472-6483"],"issn-type":[{"type":"print","value":"1472-6483"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study","name":"articletitle","label":"Article Title"},{"value":"Reproductive BioMedicine Online","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rbmo.2019.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}